Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

$20.55

-0.46 (-2.19%)

(As of 09/18/2024 ET)

Arcturus Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 8 Analyst Ratings

Based on 8 Wall Street analysts who have issued ratings for Arcturus Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 7 have given a buy rating, and 1 has given a strong buy rating for ARCT.

Consensus Price Target

$71.40
247.45% Upside

High Forecast	$90.00
Average Forecast	$71.40
Low Forecast	$48.00

According to the 8 analysts' twelve-month price targets for Arcturus Therapeutics, the average price target is $71.40. The highest price target for ARCT is $90.00, while the lowest price target for ARCT is $48.00. The average price target represents a forecasted upside of 247.45% from the current price of $20.55.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Buy	Buy	Buy	Hold
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$71.40	$68.50	$64.86	$38.78
Forecasted Upside	247.45% Upside	164.05% Upside	104.69% Upside	54.90% Upside

$25,000 into $109,616 in two months? (Ad)

Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…

Go here to watch the most recent trading workshop video at no charge.

ARCT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ARCT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Arcturus Therapeutics Stock vs. The Competition

Type	Arcturus Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.13	2.77	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	247.45% Upside	1,007.90% Upside	7.93% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/9/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight
8/12/2024	Leerink Partnrs 0 of 5 stars	L. Nsongo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/12/2024	Leerink Partners 1 of 5 stars		Initiated Coverage	Outperform	$70.00	+287.17%
8/8/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$60.00 ➝ $63.00	+235.28%
5/23/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
5/10/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$87.00 ➝ $86.00	+210.81%
Biden's Successor: The Radical Threat to YOUR Savings! (Ad) Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL. >> Get Your FREE Wealth Protection Guide <<
2/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$40.00 ➝ $48.00	+23.39%
7/17/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$35.00 ➝ $45.00	+26.98%
7/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy
11/10/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sell	$8.00 ➝ $14.00	-31.34%
11/10/2022	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$18.00	-14.65%
11/2/2022	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Equal Weight	$16.00 ➝ $25.00	+36.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:24 AM ET.

ARCT Forecast - Frequently Asked Questions

What is Arcturus Therapeutics' forecast for 2024?: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Arcturus Therapeutics is $71.40, with a high forecast of $90.00 and a low forecast of $48.00.
Should I buy or sell Arcturus Therapeutics stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARCT shares.
Does Arcturus Therapeutics's stock price have much upside?: According to analysts, Arcturus Therapeutics's stock has a predicted upside of 181.59% based on their 12-month stock forecasts.
Has Arcturus Therapeutics been upgraded by Wall Street analysts recently?: Over the previous 90 days, Arcturus Therapeutics's stock had 1 upgrade by analysts.
What analysts cover Arcturus Therapeutics?: Arcturus Therapeutics has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Leerink Partners, and Leerink Partnrs in the past 90 days.
Do Wall Street analysts like Arcturus Therapeutics more than its competitors?: Analysts like Arcturus Therapeutics more than other "medical" companies. The consensus rating for Arcturus Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ARCT compares to other companies.